BOLD
What one share of Boundless Bio holds
Pharmaceutical Preparations
The terms “we,” “us,” “our,” “our company,” “Boundless Bio,” “Boundless,” or the “Company” refer to Boundless Bio, Inc. unless otherwise stated or the context otherwise requires. Unless otherwise stated, references to particular years, quarters, months, or periods refer to our fiscal years ending December 31 and the associated quarters, months, and periods of those fiscal years.
Boundless Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.86 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$2.53 |
| Cash and investments | $0.90 |
| Book value | $2.94 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$40.65 | $0.52 | −$39.05 | — | −$101.83 |
| 2024 | — | −$3.85 | $0.15 | −$3.73 | — | $6.76 |
| 2025 | — | −$2.60 | $0.02 | −$2.11 | — | $4.40 |